Overview

Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Status:
Completed
Trial end date:
2017-10-31
Target enrollment:
Participant gender:
Summary
enrolled participants were treated orally with SOF plus a fixed dose combination of OBV/PTV/r plus RBV.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beni-Suef University
Treatments:
Sofosbuvir